United States Biotechnology & Medical Research

Enliven Therapeutics Inc (ELVN)

Track

Track

Enliven Therapeutics experienced 53 insider trading transactions over the past 90 days, totaling approximately $169 million in sales. Key executives, including the CFO and CMO, executed planned divestments. These activities follow a 77.4% stock price increase and a recent earnings report where the company missed EPS expectations by 28.9%.
Ticker: ELVN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Enliven Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Heyman Richard A. resigned from BOD
Transaction date
Proposed sale
Price
285.11
Quantity 24,684
Value US$2,253,800
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
12.38
Quantity 15,120 +23.0%
Value US$3,373,143
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
386.13
Quantity 88,833 +11.6%
Value US$670,769
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
59.35
Quantity 1,100 -4.2%
Value US$65,281
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
58.37
Quantity 3,900 -13.0%
Value US$227,650
Derynck Mika K Non-Executive Director
Transaction date
Planned sale
Price
60.21
Quantity 158,795 -100.0%
Value US$9,561,587
Derynck Mika K Director Non-Executive Director
Transaction date
Proposed sale
Price
58.04
Quantity 158,795
Value US$9,216,462
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
53.87
Quantity 123 -0.3%
Value US$6,626
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
53.38
Quantity 2,638 -5.4%
Value US$140,823
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
52.32
Quantity 2,564 -5.0%
Value US$134,143
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
51.48
Quantity 369 -0.7%
Value US$18,997
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
49.97
Quantity 324 -0.6%
Value US$16,191
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
53.92
Quantity 63 -0.3%
Value US$3,397
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
53.42
Quantity 2,184 -8.0%
Value US$116,669
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
52.39
Quantity 2,063 -7.0%
Value US$108,085
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
51.55
Quantity 459 -1.5%
Value US$23,660
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
50.05
Quantity 231 -0.8%
Value US$11,563
Collins Helen Louise Officer Officer
Transaction date
Proposed sale
Price
50.86
Quantity 15,000
Value US$762,900
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
50.84
Quantity 5,889 -12.3%
Value US$299,421
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
49.98
Quantity 4,111 -7.9%
Value US$205,482
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.00
Quantity 46,776 -0.7%
Value US$2,104,920
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.38
Quantity 787,024 -10.7%
Value US$35,715,149
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.00
Quantity 1,477 -0.7%
Value US$66,465
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.38
Quantity 24,846 -10.1%
Value US$1,127,511
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
44.75
Quantity 1,238 -2.4%
Value US$55,397
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
44.75
Quantity 1,238 -2.4%
Value US$55,397
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
43.86
Quantity 3,401 -6.1%
Value US$149,179
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
43.86
Quantity 3,401 -6.1%
Value US$149,179
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
42.79
Quantity 1,379 -2.4%
Value US$59,001
0.5
Hohl Benjamin CHIEF FINANCIAL OFFICER Officer
Transaction date
Planned sale
Price
42.79
Quantity 1,379 -2.4%
Value US$59,001
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
44.74
Quantity 1,133 -4.3%
Value US$50,694
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
44.74
Quantity 1,133 -4.3%
Value US$50,694
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
43.87
Quantity 2,599 -9.0%
Value US$114,018
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
43.87
Quantity 2,599 -9.0%
Value US$114,018
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
42.83
Quantity 1,268 -4.2%
Value US$54,305
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
42.83
Quantity 1,268 -4.2%
Value US$54,305
0.5
Hohl Benjamin Officer Officer
Transaction date
Proposed sale
Price
42.55
Quantity 18,054
Value US$768,198
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.02
Quantity 272,322 -3.6%
Value US$12,259,936
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
45.02
Quantity 9,086 -3.6%
Value US$409,052
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
35.82
Quantity 354 -0.7%
Value US$12,680
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
35.36
Quantity 1,867 -3.5%
Value US$66,012
Kunkel Lori Anne Non-Executive Director
Transaction date
Planned sale
Price
34.28
Quantity 7,779 -12.6%
Value US$266,659
Kunkel Lori Anne Board Member
Transaction date
Proposed sale
Price
35.49
Quantity 20,000
Value US$709,800
Kunkel Lori Anne Board Member
Transaction date
Proposed sale
Price
35.49
Quantity 20,000
Value US$709,800
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
41.21
Quantity 223 -0.9%
Value US$9,189
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
40.25
Quantity 1,302 -4.9%
Value US$52,402
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
39.53
Quantity 3,475 -11.6%
Value US$137,381
Collins Helen Louise Officer Officer
Transaction date
Proposed sale
Price
41.34
Quantity 15,000
Value US$620,100
Lyssikatos Joseph P Officer Officer
Transaction date
Proposed sale
Price
42.40
Quantity 25,000
Value US$1,060,000
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
48.06
Quantity 2,441 -8.9%
Value US$117,303
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
47.39
Quantity 2,419 -8.1%
Value US$114,635
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
45.81
Quantity 140 -0.5%
Value US$6,413
ANDREW PHILLIPS Former Director Non-Executive Director
Transaction date
Proposed sale
Price
38.55
Quantity 26,035
Value US$1,003,610
Lyssikatos Joseph P Officer Officer
Transaction date
Proposed sale
Price
36.59
Quantity 25,000
Value US$914,750
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
35.10
Quantity 40,000 -61.5%
Value US$1,404,024
Collins Helen Louise Officer Officer
Transaction date
Proposed sale
Price
31.15
Quantity 45,000
Value US$1,401,750
Patel Anish Officer Officer
Transaction date
Proposed sale
Price
30.81
Quantity 100,000
Value US$3,081,000
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
27.76
Quantity 5,000 -16.7%
Value US$138,800
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
30.19
Quantity 10,129 -28.8%
Value US$305,827
Collins Helen Louise CHIEF MEDICAL OFFICER Officer
Transaction date
Planned sale
Price
30.02
Quantity 29,871 -54.4%
Value US$896,811
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-04 2026-09-04 PrS Proposed sale
Heyman Richard A.

resigned from BOD
24,684
285.11
US$2,253,800 		24,684 285.11 US$2,253,800
2026-08-19 2026-08-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
15,120 +23.0%
12.38
US$3,373,143 		15,120 +23.0% 12.38 US$3,373,143
2026-08-19 2026-08-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
88,833 +11.6%
386.13
US$670,769 		88,833 +11.6% 386.13 US$670,769
2026-08-19 2026-08-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,100 -4.2%
59.35
US$65,281 		1,100 -4.2% 59.35 US$65,281
2026-08-19 2026-08-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
3,900 -13.0%
58.37
US$227,650 		3,900 -13.0% 58.37 US$227,650
2026-08-06 2026-08-04 PlS Planned sale
Derynck Mika K
Non-Executive Director
158,795 -100.0%
60.21
US$9,561,587 		158,795 -100.0% 60.21 US$9,561,587
2026-08-04 2026-08-04 PrS Proposed sale
Derynck Mika K

Director

Non-Executive Director
158,795
58.04
US$9,216,462 		158,795 58.04 US$9,216,462
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
123 -0.3%
53.87
US$6,626 		123 -0.3% 53.87 US$6,626
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
2,638 -5.4%
53.38
US$140,823 		2,638 -5.4% 53.38 US$140,823
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
2,564 -5.0%
52.32
US$134,143 		2,564 -5.0% 52.32 US$134,143
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
369 -0.7%
51.48
US$18,997 		369 -0.7% 51.48 US$18,997
2026-07-21 2026-07-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
324 -0.6%
49.97
US$16,191 		324 -0.6% 49.97 US$16,191
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
63 -0.3%
53.92
US$3,397 		63 -0.3% 53.92 US$3,397
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,184 -8.0%
53.42
US$116,669 		2,184 -8.0% 53.42 US$116,669
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,063 -7.0%
52.39
US$108,085 		2,063 -7.0% 52.39 US$108,085
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
459 -1.5%
51.55
US$23,660 		459 -1.5% 51.55 US$23,660
2026-07-21 2026-07-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
231 -0.8%
50.05
US$11,563 		231 -0.8% 50.05 US$11,563
2026-07-17 2026-07-17 PrS Proposed sale
Collins Helen Louise

Officer

Officer
15,000
50.86
US$762,900 		15,000 50.86 US$762,900
2026-07-08 2026-07-06 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
5,889 -12.3%
50.84
US$299,421 		5,889 -12.3% 50.84 US$299,421
2026-07-08 2026-07-06 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
4,111 -7.9%
49.98
US$205,482 		4,111 -7.9% 49.98 US$205,482
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
46,776 -0.7%
45.00
US$2,104,920 		46,776 -0.7% 45.00 US$2,104,920
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
787,024 -10.7%
45.38
US$35,715,149 		787,024 -10.7% 45.38 US$35,715,149
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,477 -0.7%
45.00
US$66,465 		1,477 -0.7% 45.00 US$66,465
2026-06-24 2026-06-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
24,846 -10.1%
45.38
US$1,127,511 		24,846 -10.1% 45.38 US$1,127,511
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
1,477
45.96
US$67,883 		1,477 45.96 US$67,883
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
1,477
45.96
US$67,883 		1,477 45.96 US$67,883
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
24,846
45.96
US$1,141,922 		24,846 45.96 US$1,141,922
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
24,846
45.96
US$1,141,922 		24,846 45.96 US$1,141,922
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
46,776
45.96
US$2,149,825 		46,776 45.96 US$2,149,825
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
46,776
45.96
US$2,149,825 		46,776 45.96 US$2,149,825
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
787,024
45.96
US$36,171,623 		787,024 45.96 US$36,171,623
2026-06-22 2026-06-22 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
787,024
45.96
US$36,171,623 		787,024 45.96 US$36,171,623
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
1,747
45.96
US$80,292 		1,747 45.96 US$80,292
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
1,747
45.96
US$80,292 		1,747 45.96 US$80,292
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
29,385
45.96
US$1,350,535 		29,385 45.96 US$1,350,535
2026-06-22 2026-06-22 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
29,385
45.96
US$1,350,535 		29,385 45.96 US$1,350,535
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,238 -2.4%
44.75
US$55,397 		1,238 -2.4% 44.75 US$55,397
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,238 -2.4%
44.75
US$55,397 		1,238 -2.4% 44.75 US$55,397
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
3,401 -6.1%
43.86
US$149,179 		3,401 -6.1% 43.86 US$149,179
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
3,401 -6.1%
43.86
US$149,179 		3,401 -6.1% 43.86 US$149,179
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,379 -2.4%
42.79
US$59,001 		1,379 -2.4% 42.79 US$59,001
2026-06-22 2026-06-17 PlS Planned sale
0.5
Hohl Benjamin

CHIEF FINANCIAL OFFICER

Officer
1,379 -2.4%
42.79
US$59,001 		1,379 -2.4% 42.79 US$59,001
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,133 -4.3%
44.74
US$50,694 		1,133 -4.3% 44.74 US$50,694
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,599 -9.0%
43.87
US$114,018 		2,599 -9.0% 43.87 US$114,018
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-06-22 2026-06-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,268 -4.2%
42.83
US$54,305 		1,268 -4.2% 42.83 US$54,305
2026-06-17 2026-06-17 PrS Proposed sale
0.5
Hohl Benjamin

Officer

Officer
18,054
42.55
US$768,198 		18,054 42.55 US$768,198
2026-06-17 2026-06-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
272,322 -3.6%
45.02
US$12,259,936 		272,322 -3.6% 45.02 US$12,259,936
2026-06-17 2026-06-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
9,086 -3.6%
45.02
US$409,052 		9,086 -3.6% 45.02 US$409,052
2026-06-15 2026-06-15 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
10,243
42.36
US$433,893 		10,243 42.36 US$433,893
2026-06-15 2026-06-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder
272,322
42.36
US$11,535,560 		272,322 42.36 US$11,535,560
2026-06-15 2026-06-15 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
9,086
42.36
US$384,883 		9,086 42.36 US$384,883
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
354 -0.7%
35.82
US$12,680 		354 -0.7% 35.82 US$12,680
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
1,867 -3.5%
35.36
US$66,012 		1,867 -3.5% 35.36 US$66,012
2026-06-09 2026-06-05 PlS Planned sale
Kunkel Lori Anne
Non-Executive Director
7,779 -12.6%
34.28
US$266,659 		7,779 -12.6% 34.28 US$266,659
2026-06-05 2026-06-05 PrS Proposed sale
Kunkel Lori Anne

Board Member
20,000
35.49
US$709,800 		20,000 35.49 US$709,800
2026-06-05 2026-06-05 PrS Proposed sale
Kunkel Lori Anne

Board Member
20,000
35.49
US$709,800 		20,000 35.49 US$709,800
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
223 -0.9%
41.21
US$9,189 		223 -0.9% 41.21 US$9,189
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
1,302 -4.9%
40.25
US$52,402 		1,302 -4.9% 40.25 US$52,402
2026-05-20 2026-05-18 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
3,475 -11.6%
39.53
US$137,381 		3,475 -11.6% 39.53 US$137,381
2026-05-18 2026-05-18 PrS Proposed sale
Collins Helen Louise

Officer

Officer
15,000
41.34
US$620,100 		15,000 41.34 US$620,100
2026-04-30 2026-04-30 PrS Proposed sale
Lyssikatos Joseph P

Officer

Officer
25,000
42.40
US$1,060,000 		25,000 42.40 US$1,060,000
2026-04-21 2026-04-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,441 -8.9%
48.06
US$117,303 		2,441 -8.9% 48.06 US$117,303
2026-04-21 2026-04-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
2,419 -8.1%
47.39
US$114,635 		2,419 -8.1% 47.39 US$114,635
2026-04-21 2026-04-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
140 -0.5%
45.81
US$6,413 		140 -0.5% 45.81 US$6,413
2026-03-31 2026-03-31 PrS Proposed sale
ANDREW PHILLIPS

Former Director

Non-Executive Director
26,035
38.55
US$1,003,610 		26,035 38.55 US$1,003,610
2026-03-31 2026-03-31 PrS Proposed sale
Lyssikatos Joseph P

Officer

Officer
25,000
36.59
US$914,750 		25,000 36.59 US$914,750
2026-03-27 2026-03-25 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
40,000 -61.5%
35.10
US$1,404,024 		40,000 -61.5% 35.10 US$1,404,024
2026-03-25 2026-03-25 PrS Proposed sale
Collins Helen Louise

Officer

Officer
45,000
31.15
US$1,401,750 		45,000 31.15 US$1,401,750
2026-03-24 2026-03-24 PrS Proposed sale
Patel Anish

Officer

Officer
100,000
30.81
US$3,081,000 		100,000 30.81 US$3,081,000
2026-03-19 2026-03-17 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
5,000 -16.7%
27.76
US$138,800 		5,000 -16.7% 27.76 US$138,800
2026-03-11 2026-03-10 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
10,129 -28.8%
30.19
US$305,827 		10,129 -28.8% 30.19 US$305,827
2026-03-11 2026-03-09 PlS Planned sale
Collins Helen Louise

CHIEF MEDICAL OFFICER

Officer
29,871 -54.4%
30.02
US$896,811 		29,871 -54.4% 30.02 US$896,811
Explore more

More insider trading research around Enliven Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America